COVID-19 大流行对冈比亚农村肺炎球菌疫苗接种方案(PVS)临床试验的影响
PVS 研究是一项在冈比亚农村 68 个地理集群婴儿中开展的非劣效性干预试验,随机分配两种肺炎球菌疫苗接种方案。2020 年 3 月至 9 月因 COVID-19 疫情多次暂停入组,期间继续安全性监测,已入组婴儿按原随机方案接种。2021 年 4 月正式审查认为疫情未损害试验科学有效性,试验按方案继续。
要点
- PVS 试验在 68 个地理集群婴儿中随机分配两种肺炎球菌疫苗接种方案,为非劣效性干预试验。
- 2020 年 3 月 26 日至 7 月 1 日、8 月 5 日至 9 月 1 日暂停入组,期间继续安全性监测但受干扰。
- 2021 年 4 月正式审查认为疫情未损害试验科学有效性,试验按方案继续。
核心结论
- 2021 年 4 月正式审查结论认为 COVID-19 大流行未损害 PVS 试验的科学有效性,试验应按方案继续。
- COVID-19 对 PVS 及其他临床试验的持续挑战还将存在一段时间。
研究设计与样本
- PVS 研究是一项非劣效性干预试验,研究对象为居住在 68 个地理集群的婴儿,随机分配两种肺炎球菌疫苗接种方案。
- 自 2019 年 9 月起,研究区域内所有婴儿在研究区域的所有扩大免疫规划(EPI)诊所均有资格入组。
- 临床终点监测在研究区域内全部 11 家卫生机构进行。
- PVS 由伦敦卫生与热带医学院(LSHTM)的冈比亚医学研究理事会单位(MRCG)与冈比亚卫生部(MoH)合作开展。
主要发现
- MRCG 于 2020 年 3 月 26 日指示干预性研究暂停入组,冈比亚于 2020 年 3 月 28 日宣布公共卫生紧急状态。
- PVS 入组于 2020 年 7 月 1 日重启,2020 年 8 月 5 日再次暂停(此前 2020 年 7 月下旬冈比亚 COVID-19 病例急剧增加),2020 年 9 月 1 日再次重启。
- 入组暂停期间,2020 年 3 月 26 日前已入组婴儿继续按基于居住村随机分配的 PCV 方案接种,其他所有婴儿接受标准 PCV 方案。
- 入组暂停期间,PVS 继续在卫生机构进行安全性监测,尽管受到干扰。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic represents an unprecedented challenge for clinical research. The Pneumococcal Vaccine Schedules (PVS) study is a non-inferiority, interventional trial in which infants resident in 68 geographic clusters are randomised to two different schedules for pneumococcal vaccination. From September 2019 onwards, all infants resident in the study area became eligible for trial enrolment at all Expanded Programme on Immunisation (EPI) clinics in the study area. Surveillance for clinical endpoints is conducted at all 11 health facilities in the study area. PVS is conducted as a collaboration between the Medical Research Council Unit The Gambia (MRCG) at LSHTM and the Gambian Ministry of Health (MoH). The COVID-19 pandemic caused many disruptions to PVS. MRCG instructed interventional studies that participant enrolment be suspended on 26 March 2020, and a public health emergency was declared in The Gambia on 28 March 2020. Enrolment in PVS restarted on 1 July 2020 and was suspended again on 5 August 2020 after The Gambia experienced a sharp increase in COVID-19 cases in late July 2020 and restarted again on 1 September 2020. During periods of suspended enrolment of infants at EPI clinics, PVS continued safety surveillance at health facilities, albeit with disruptions. During the periods of suspended enrolment, infants who had been enrolled before 26 March 2020 continued to receive the PCV schedule to which they had been randomly allocated based on their village of residence, whereas all other infants received the standard PCV schedule. Throughout 2020 and 2021, the trial faced numerous technical and operational challenges: disruption to MoH delivery of EPI services and clinical care at health facilities; episodes of staff illness and isolation; disruption of MRCG transport, procurement, communications and human resource management; and also a range of ethical, regulatory, sponsorship, trial monitoring and financial challenges. In April 2021, a formal review concluded that the pandemic had not compromised the scientific validity of PVS and that the trial should continue as per protocol. The continuing challenges that COVID-19 poses to PVS, and other clinical trials will persist for some time.
引用
- Hossain I, Osei I, Lobga G, et al. Impact of the COVID-19 pandemic on a clinical trial of pneumococcal vaccine scheduling (PVS) in rural Gambia. Trials. 2023. PMID: 37055788. doi:10.1186/s13063-023-07298-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。